G1 Therapeutics, Inc.
Clinical trials sponsored by G1 Therapeutics, Inc., explained in plain language.
-
New drug combo may shield bone marrow in aggressive lung cancer
Disease control CompletedThis study tested whether adding the drug trilaciclib to standard chemotherapy and immunotherapy could protect bone marrow and the immune system in people with advanced small cell lung cancer. About 100 participants received either trilaciclib or a placebo alongside their cancer …
Phase: PHASE2 • Sponsor: G1 Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Could a simple shot shield cancer patients from chemo's worst side effects?
Symptom relief CompletedThis study tested a drug called trilaciclib in 123 people with advanced small cell lung cancer who were getting chemotherapy. The goal was to see if it could protect their bone marrow and immune system from damage caused by chemo, reducing side effects like low white blood cell c…
Phase: PHASE1, PHASE2 • Sponsor: G1 Therapeutics, Inc. • Aim: Symptom relief
Last updated May 26, 2026 09:04 UTC